Investor Presentaiton

Patient Disposition ITT Population Few patients withdrew and withdrawal rates were similar across treatment groups Premature discontinuation of randomized treatment was balanced across treatment groups Known vital status was high in both trials across both treatment groups ESA asceND ND NON-DIALYSIS asceND D Darbepoetin Daprodustat Daprodustat alfa DIALYSIS Randomized, n 2964 Randomized, n 3872 Intent-to-treat, n 1487 1477 Intent-to-treat, n 1937 1935 Withdrew from trial, % 8 8 Withdrew from trial, % 3 Completed the trial 92 Prematurely discontinued RT, % 53 Did not prematurely discontinue RT 47 47 Known vital status, % 98 Unknown vital status 2 28 N 92 Completed the trial 97 97 53 Prematurely discontinued RT, % Did not prematurely discontinue RT 38 62 98 Known vital status, % 99 310022 38 62 99 2 Unknown vital status <1 <1 ITT, intent-to-treat; RT, randomized treatment. Note: In ASCEND-D, 5 daprodustat and 3 ESA patients were randomized but never treated. In ASCEND-ND, 2 darbepoetin alfa patients were randomized but never treated. 10

View entire presentation